Verification evidence is still being completed.
PDF / print export
TolerogenixX
Heidelberg, Germany
- Verified lead
- Matthias Schaier
- Lead status
- STATUS: VERIFIED MARCH 2026
- Leadership verification
- Chief Executive Officer
- 2026 technical specialization
- Cell Therapy, Autoimmune Disease, Tolerogenic Dendritic Cells, Transplant Medicine, and Clinical Development
- Review cycle
- May 2026
- Full address
- Im Neuenheimer Feld 582, 69120 Heidelberg, Germany
- Site coordinates
- Verification evidence is still being completed.
- Editorial review
- Memel Biotech editorial review
- Official leadership source
- Official TolerogenixX contact page confirming the Heidelberg address.
- Editorial note
- TolerogenixX is published because official company materials confirm current leadership, Heidelberg operating address, and a real cell-therapy platform.
Cell Therapy, Autoimmune Disease, Tolerogenic Dendritic Cells, Transplant Medicine, and Clinical Development
Official leadership disclosure, Official Heidelberg address disclosure, Cell-therapy platform claim
TolerogenixX is published because official company materials confirm current leadership, Heidelberg operating address, and a real cell-therapy platform.
Review coverage
Leadership
Facility
Certifications
Capabilities
Partners
Sources
Quality
Editorial verificationMemel Biotech directory review sign-off
Report generated02 Jun 2026, 01:40
Company profile · Heidelberg, Germany
TolerogenixX
Cell Therapy, Autoimmune Disease, Tolerogenic Dendritic Cells, Transplant Medicine, and Clinical Development · Clinical-stage cell-therapy platform
TolerogenixX runs cell-therapy development, autoimmune disease programs, and transplant-related tolerance programs in Heidelberg, Germany.
- Lead
- Matthias Schaier (verified ↗)
- Address
- Im Neuenheimer Feld 582, 69120 Heidelberg, Germany (source ↗)
- Compliance
- Not yet on record
- Last reviewed
- 22 Mar 2026 (2mo ago)
- Scale
- Clinical-stage cell-therapy platform
- Capabilities
- Cell-Therapy Development · Autoimmune Disease Programs · Transplant-Related Tolerance Programs
- Founded
- 2014
- Headcount
- 11-50
- Company page (open ↗)
Clinical profileSTATUS: VERIFIED MARCH 2026
Matthias Schaier
Chief Executive Officer
Full addressIm Neuenheimer Feld 582, 69120 Heidelberg, Germany
Site coordinatesVerification evidence is still being completed.
Review cycleMay 2026
Clinical-stage cell-therapy platform
Heidelberg, Germany. Cell Therapy, Autoimmune Disease, Tolerogenic Dendritic Cells, Transplant Medicine, and Clinical Development. Review completed on 22 Mar 2026.
German corporate and advanced-therapy oversight
Official leadership disclosure, Official Heidelberg address disclosure, Cell-therapy platform claim
Cell Therapy, Autoimmune Disease, Tolerogenic Dendritic Cells, Transplant Medicine, and Clinical Development
TolerogenixX is published because official company materials confirm current leadership, Heidelberg operating address, and a real cell-therapy platform.
Editorial note
TolerogenixX is published because official company materials confirm current leadership, Heidelberg operating address, and a real cell-therapy platform.
FULL TRUST REVIEW COMPLETE
Shown only when all seven trust checks are fully mapped in the directory.
Current review cycleMarch 2026
Capabilities
Core capabilities
Primary declared technical activities and areas of operating focus.
Cell-Therapy Development
Autoimmune Disease Programs
Transplant-Related Tolerance Programs
Verification source dossier
Verification source dossier
Official source set used to support leadership, physical-site, certification, and watch-note evidence.
Infrastructure
Declared infrastructure
Cell-processing workflow
ATMP development systems
Clinical program infrastructure
Regulatory posture
Quality system coverage
GMP / GLP / ISO-13485 / FDA-Inspected are global quality-system standards. "Verified active" means the directory confirmed the certification is current; "Review in progress" means the cert status is currently being re-verified.
- GMP
- REVIEW IN PROGRESS 2026
- GLP
- REVIEW IN PROGRESS 2026
- ISO-13485
- REVIEW IN PROGRESS 2026
- FDA-Inspected
- REVIEW IN PROGRESS 2026
Verification history
Verification history
22 Mar 2026: Executive identity confirmed via official management disclosure.
22 Mar 2026: Full trust review completed.
FAQ
Frequently asked questions
- Where is TolerogenixX located?
- TolerogenixX operates from Im Neuenheimer Feld 582, 69120 Heidelberg, Germany, Heidelberg, Germany.
- Who runs TolerogenixX?
- TolerogenixX is led by Matthias Schaier, Chief Executive Officer. Verified 22 Mar 2026.
- What does TolerogenixX do?
- TolerogenixX runs cell-therapy development, autoimmune disease programs, and transplant-related tolerance programs in Heidelberg, Germany. Core capabilities: Cell-Therapy Development, Autoimmune Disease Programs, Transplant-Related Tolerance Programs.
Editorial context
Related technical briefs
Briefs that name Heidelberg as a covered market or city.